In estrogen receptor-positive, HER2-negative (ER+/HER2-) early-stage breast cancer, tumors with lower ER and higher PD-1 were more likely to respond to neoadjuvant immune checkpoint inhibitors (ICI) (3,4). This evidence concerns the gene ESR1 and breast cancer.